<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="publisher-id">nar</journal-id><journal-id journal-id-type="hwp">nar</journal-id><journal-title>Nucleic Acids Research</journal-title><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/nar/gkp117</article-id><article-id pub-id-type="publisher-id">gkp117</article-id><article-categories><subj-group subj-group-type="heading"><subject>RNA</subject></subj-group></article-categories><title-group><article-title>Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wickramasinghe</surname><given-names>Nalinie S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Manavalan</surname><given-names>Tissa T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dougherty</surname><given-names>Susan M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Riggs</surname><given-names>Krista A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yong</given-names></name></contrib><contrib contrib-type="author"><name><surname>Klinge</surname><given-names>Carolyn M.</given-names></name><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff>Department of Biochemistry &#x00026; Molecular Biology, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY 40292, USA</aff><author-notes><corresp id="COR1">*To whom correspondence should be addressed. Tel: <phone>+1 502 852 3668</phone>; Fax: <fax>+1 502 852 6222</fax>; Email: <email>carolyn.klinge@louisville.edu</email></corresp></author-notes><!--For NAR both ppub and collection dates generated for PMC processing 1/27/05 beck--><pub-date pub-type="collection"><month>5</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2009</year></pub-date><pub-date pub-type="epub"><month>5</month><year>2009</year></pub-date><volume>37</volume><issue>8</issue><fpage>2584</fpage><lpage>2595</lpage><history><date date-type="received"><day>3</day><month>12</month><year>2008</year></date><date date-type="rev-recd"><day>3</day><month>2</month><year>2009</year></date><date date-type="accepted"><day>3</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 The Author(s)</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Select changes in microRNA (miRNA) expression correlate with estrogen receptor &#x003b1; (ER&#x003b1;) expression in breast tumors. miR-21 is higher in ER&#x003b1; positive than negative tumors, but no one has examined how estradiol (E<sub>2</sub>) regulates miR-21 in breast cancer cells. Here we report that E<sub>2</sub> inhibits miR-21 expression in MCF-7 human breast cancer cells. The E<sub>2</sub>-induced reduction in miR-21 was inhibited by 4-hydroxytamoxifen (4-OHT), ICI 182 780 (Faslodex), and siRNA ER&#x003b1; indicating that the suppression is ER&#x003b1;-mediated. ER&#x003b1; and ER&#x003b2; agonists PPT and DPN inhibited and 4-OHT increased miR-21 expression. E<sub>2</sub> increased luciferase activity from reporters containing the miR-21 recognition elements from the 3&#x02032;-UTRs of miR-21 target genes, corroborating that E<sub>2</sub> represses miR-21 expression resulting in a loss of target gene suppression. The E<sub>2</sub>-mediated decrease in miR-21 correlated with increased protein expression of endogenous miR-21-targets Pdcd4, PTEN and Bcl-2. siRNA knockdown of ER&#x003b1; blocked the E<sub>2</sub>-induced increase in Pdcd4, PTEN and Bcl-2. Transfection of MCF-7 cells with antisense (AS) to miR-21 mimicked the E<sub>2</sub>-induced increase in Pdcd4, PTEN and Bcl-2. These results are the first to demonstrate that E<sub>2</sub> represses the expression of an oncogenic miRNA, miR-21, by activating estrogen receptor in MCF-7 cells.</p></abstract></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Although the precise sequence of events leading to breast tumors are not understood, lifetime exposure to estrogens is widely accepted as a major risk factor for the development of breast cancer. Estrogens promote cell replication by binding to the estrogen receptors &#x003b1; and &#x003b2; (ER&#x003b1; and ER&#x003b2;). Ligand-activated ER acts genomically by binding directly to estrogen response elements (EREs) or by a &#x02018;tethering mechanism&#x02019;, e.g. by interacting with AP-1 (<xref ref-type="bibr" rid="B1">1</xref>) or Sp1 (<xref ref-type="bibr" rid="B2">2</xref>). These interactions recruit coregulators to initiate chromatin remodeling resulting in increased gene transcription (<xref ref-type="bibr" rid="B3">3</xref>). ER can also suppress target gene transcription, although the mechanisms involved are unresolved (<xref ref-type="bibr" rid="B4">4</xref>). In addition to its ER-mediated, genomic activity, E<sub>2</sub> also has &#x02018;non-genomic&#x02019; or &#x02018;membrane-initiated&#x02019; effects, i.e. independent of ER-mediated transcription, that occur within minutes after estradiol (E<sub>2</sub>), or other ER ligand, administration (<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>).</p><p>Inhibition of estrogen action is used as the adjuvant therapy of choice to treat both pre- and post-menopausal women with breast cancer. The anti-estrogen/Selective ER Modulator (SERM) tamoxifen (TAM) is the &#x02018;gold standard&#x02019; of treatment of women with ER positive tumors (<xref ref-type="bibr" rid="B7">7</xref>). TAM is a SERM because it has mixed agonist/antagonist activity in a cell- and gene-specific manner whereas Faslodex (Fulvestrant, ICI 182 780) has pure antiestrogen activity (<xref ref-type="bibr" rid="B8">8</xref>). Ablation of endogenous estrogen production using aromatase inhibitors (AIs, e.g. anastrozole, letrozole and exemestane) has an efficacy greater than TAM in preventing disease recurrence in post-menopausal breast cancer patients (<xref ref-type="bibr" rid="B9">9</xref>). Together, these data demonstrate the importance of endogenous estrogens in promoting breast cancer recurrence.</p><p>MicroRNAs (miRNAs) are a class of naturally occurring, small, non-coding RNA molecules distinct from small interfering RNAs (siRNAs) (<xref ref-type="bibr" rid="B10 B11 B12">10&#x02013;12</xref>). miRNA genes are mostly transcribed by RNA polymerase II, processed by Drosha into short hairpin RNAs that are exported from the nucleus, and processed by Dicer to form mature 21&#x02013;25 nucleotide miRNAs which are transferred to Argonaute proteins in RISC. miRNAs bind to the 3&#x02032;-untranslated region (3&#x02032; UTR) of target mRNAs and either block the translation of the message or target the mRNA transcript to be degraded (<xref ref-type="bibr" rid="B13">13</xref>). miRNAs may also increase translation of select mRNAs in a cell cycle-dependent manner (<xref ref-type="bibr" rid="B14">14</xref>).</p><p>The human genome contains &#x0003e;700 miRNAs (<xref ref-type="bibr" rid="B15">15</xref>) and miRNAs are expressed in a tissue-specific manner (<xref ref-type="bibr" rid="B16">16</xref>). Each miRNA targets &#x0223c;200 transcripts directly or indirectly (<xref ref-type="bibr" rid="B17">17</xref>). Aberrant patterns of miRNA expression have been reported in human breast cancer (<xref ref-type="bibr" rid="B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40">16&#x02013;40</xref>). A number of genes involved in breast cancer progression have been identified by <italic>in silico</italic> analysis to be targets of miRNAs that are deregulated in breast cancer (<xref ref-type="bibr" rid="B41">41</xref>) and some, e.g. AIB1 have been experimentally proven (<xref ref-type="bibr" rid="B42">42</xref>). We recently reported that miR-21 downregulates the translation of human <italic>PDCD4</italic>, a tumor suppressor in MCF-7 cells (<xref ref-type="bibr" rid="B43">43</xref>). Although miR-21 was identified as an &#x02018;oncomiR&#x02019;, was the most significantly up-regulated miRNA in breast tumor biopsies (<xref ref-type="bibr" rid="B37">37</xref>), and was significantly higher in ER&#x003b1;+ than ER&#x003b1;&#x02013; breast tumors (<xref ref-type="bibr" rid="B40">40</xref>), no one has examined whether E<sub>2</sub> or SERMs regulate miR-21 expression in human breast cancer cells.</p><p>In this study, we tested the hypothesis that miR-21, an &#x02018;oncomiR&#x02019;, is regulated by E<sub>2</sub> in MCF-7 breast cancer cells. Although E<sub>2</sub> increases proliferation of MCF-7 cells, we found that E<sub>2</sub> inhibits miR-21 expression. Experiments were performed to test the effect of E<sub>2</sub> on targets of miR-21. <italic>In silico</italic> analysis identified miR-21 seed elements in six target genes and these miRNA recognition elements (MREs) were cloned into the 3&#x02032;UTR of a <italic>Renilla</italic> reporter for subsequent transcriptional evaluation and examination of the effect of antisense to miR-21 on <italic>Renilla</italic> luciferase. Antisense to miR-21 was used to confirm the importance of miR-21-MRE interaction in response to E<sub>2</sub>. Importantly, the E<sub>2</sub>-mediated decrease in miR-21 correlated with increased expression of miR-21-targets PDCD4, PTEN and Bcl-2 at the protein level. These results identify miR-21 as an E<sub>2</sub>-ER- regulated miRNA in MCF-7 cells.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Cells and treatments</title><p>MCF-7 cells were purchased from ATCC and maintained as previously described (<xref ref-type="bibr" rid="B44">44</xref>). 17&#x003b2;-estradiol (E<sub>2</sub>), 4-hydroxytamoxifen (4-OHT), Actinomycin D (ActD, a transcriptional inhibitor) and cycloheximide (CHX, a protein synthesis inhibitor) were purchased from Sigma; ICI 182 780 (ICI), 4,4&#x02032;,4&#x02032;&#x02032;-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, an ER&#x003b1;-selective agonist) and 2,3-<italic>bis</italic>(4-hydroxyphenyl)-propionitrile (DPN, an ER&#x003b2;-selective agonist) were purchased from Tocris. Prior to ligand treatment, the medium was replaced with phenol red-free IMEM supplemented with 5% dextran charcoal-stripped FBS (DCC-FBS) for 48 h (serum-starved). Where indicated, MCF-7 cells were pre-treated with 10 &#x003bc;g/ml ActD or 10 &#x003bc;g/ml CHX, for 1 h before ligand treatment. Cells were treated with ethanol (EtOH, the vehicle control) 0.01% final volume, 10 nM E<sub>2</sub>, 100 nM 4-OHT, 10 nM PPT, or 10 nM DPN, alone or in combination with 100 nM ICI for 6 h. For the indicated experiments, cells were pretreated with 100 nM ICI for 6 h prior to EtOH or E<sub>2</sub> treatment.</p></sec><sec><title>miRNA microarray</title><p>RNA was isolated from MCF-7 cells treated with EtOH or 10 nM E<sub>2</sub> for 6 h using the mirVana miRNA Isolation Kit from Ambion (Austin, TX) and was sent to LC Sciences (Houston, TX) (<ext-link ext-link-type="uri" xlink:href="http://lcsciences.com/">http://lcsciences.com/</ext-link>) where the RNA samples were labeled either with Cy3 or Cy5 and were hybridized with two identical, dual-color miRNA microarray chips (MRA-1001, LC Sciences). The array contains probes to detect mature miRNA sequences as well as pre-miRNAs in the Sanger miRNA registry (<ext-link ext-link-type="uri" xlink:href="http://microrna.sanger.ac.uk/sequences/">http://microrna.sanger.ac.uk/sequences/</ext-link>). Each human miRNA on the chip contains seven redundancies for each sequence to increase sensitivity. Microarray analysis was performed by LCS including background subtraction and data normalization to the statistical median of all detectable transcripts. Two lists of differentially expressed transcripts (based on a <italic>P</italic>-value &#x0003c; 0.01) from two chips were merged into one list and a statistical correlation between the two sets of data was calculated.</p></sec><sec><title>Constructs of miRNA-recognition elements (MREs)</title><p>For MRE sequences, synthetic DNA oligonucleotides (&#x0223c;35 bp) containing the MRE sequence (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Table 1</ext-link>) and &#x0223c;5 bp adjacent sequences from each end were annealed and ligated into the <italic>Not</italic>I/<italic>Xho</italic>I sites located in the 3&#x02032;UTR region of the pRL-TK <italic>Renilla</italic> luciferase reporter from Promega. Full-length (FL) 3&#x02032;-UTRs of <italic>PDCD4</italic> and <italic>RASA1</italic> were amplified by PCR and inserted into the phRL-TK vector, similarly. All constructs were confirmed by DNA sequencing.</p></sec><sec><title>Quantitative real-time PCR (Q-PCR) analysis of miRNA and mRNA expression</title><p>miRNA-enriched total RNA was extracted from MCF-7 cells using the <italic>mir</italic>Vana miRNA isolation kit (Ambion). Quantification of miRNAs was performed using TaqMan MicroRNA Assays (Applied Biosystems). U6 RNA was used for normalization of miRNA expression. For analysis of <italic>PTEN</italic>, <italic>PDCD4</italic>, <italic>BCL2</italic> and <italic>TMEM49</italic> mRNA expression, RNA was extracted using Trizol and quantitation was performed using TaqMan primers and probes from ABI using 18S for normalization. Analysis and fold change were determined using the comparative threshold cycle (Ct) method. The change in miRNA or mRNA expression was calculated as fold-change, i.e. relative to EtOH-treated (control).</p></sec><sec><title>Western blot</title><p>Cells were treated as indicated in individual figure and whole cell extracts (WCE) were prepared in modified RIPA buffer as described (<xref ref-type="bibr" rid="B22">22</xref>). Western analysis was performed and quantitated as described (<xref ref-type="bibr" rid="B19">19</xref>). Membranes were probed with ER&#x003b1; antibodies AER320 from NeoMarkers or HC-20 from Santa Cruz Biotechnology, ER&#x003b2; antibody H150 (Santa Cruz Biotechnology), polyclonal PDCD4 antibody from Genetex, monoclonal PTEN antibody from Cell Signaling, or monoclonal Bcl-2 antibody from Assay Designs. Membranes were stripped and re-probed for &#x003b2;-actin (Sigma).</p></sec><sec><title>Transient transfection</title><p>MCF-7 cells were plated in 24-well plates at a density of 1.5 &#x000d7; 10<sup>4</sup> cells/well in phenol red-free OPTI-MEM I reduced serum medium (GIBCO/Invitrogen) supplemented with 10% DCC-FBS. Transient transfection was performed using FuGene6 (Roche). For experiments in <xref ref-type="fig" rid="F2">Figures 2</xref> and <xref ref-type="fig" rid="F3">3</xref>A, each well received 10 ng of pGL3-pro-luciferase reporter (Promega) as a control and 10 ng of pRL-TK, <italic>Renilla</italic> luciferase reporter (Promega) containing the indicated MRE or 3&#x02032;-UTR of miR-21 target genes. For some experiments, cells were also co-transfected with 2&#x02032;-O-Me-anti-miR-21 [antisense (AS)-miR-21] and the control used was the negative control #1 from Ambion: a random-sequence 2&#x02032;-O-Me modified RNA molecule that has been extensively tested in many human cell lines and tissues and validated to not produce any identifiable effect on known miRNA function (<xref ref-type="bibr" rid="B23">23</xref>). For <xref ref-type="fig" rid="F3">Figure 3</xref>A, MCF-7 cells were transfected with 250 ng of pmiR-21s-luc or pmiR-21as-luc reporters described in (<xref ref-type="bibr" rid="B45">45</xref>) and 5 ng pRL-TK (control). Twenty-four hours after transfection, triplicate wells were treated with EtOH (vehicle control), E<sub>2</sub>, 4-OHT or ICI 182 780 as indicated in the figure legend. The cells were harvested 30 h post-treatment using Promega's Passive Lysis buffer. Luciferase and <italic>Renilla</italic> luciferase activities were determined using Promega's Dual Luciferase assay. For <xref ref-type="fig" rid="F2">Figure 2</xref>, <italic>Renilla</italic> luciferase was normalized by Firefly luciferase to correct for transfection efficiency. For <xref ref-type="fig" rid="F3">Figure 3</xref>A, Firefly luciferase was normalized to <italic>Renilla</italic> luciferase. Fold induction was determined by dividing the averaged normalized values from each treatment by the EtOH value for each transfection condition within that experiment. Values were averaged from multiple experiments as indicated in the figure legends.</p></sec><sec><title>AS-control and AS-miR-21 transfection</title><p>MCF-7 cells were transfected with AS- duplexes and control-nonspecific siRNA obtained from Ambion using Lipofectamine RNAiMAX from Invitrogen according to the manufacturer's protocol. Twenty-four hours post-transfection, the medium was replaced with phenol red-free IMEM with 5% DCC for 48 h and the cells were treated with ethanol (EtOH) vehicle control, 10 nM E<sub>2</sub>, 10 nM PPT or 10 nM DPN for 24 h prior. Total RNA was isolated for Q-PCR analysis and WCEs were prepared and stored for 24 h at &#x02212;80&#x000b0;C until western blot analysis. Each experiment was repeated for a total of three biological replicates. Western blots were quantified as above and the ratio of each protein/&#x003b2;-actin in the AS-control in EtOH-treated samples was set to 1 in each experiment.</p></sec><sec><title>ER&#x003b1; and ER&#x003b2; knockdown by siRNA</title><p>MCF-7 cells were transfected with siRNA duplexes and control-nonspecific siRNA obtained from New England Biolabs (<xref ref-type="bibr" rid="B44">44</xref>). Forty-eight hours post-transfection, the cells were treated with 10 nM E<sub>2</sub>, 10 nM PPT or 10 nM DPN for 6 h for mRNA analysis, or 24 h for protein analysis. Total RNA was isolated for Q-PCR analysis and WCEs were prepared and stored for 24 h at &#x02212;80&#x000b0;C until western blot analysis.</p></sec><sec><title>Statistics</title><p>Statistical analyses were performed using Student's <italic>t</italic>-test or one-way ANOVA followed by Student&#x02013;Newman&#x02013;Keuls or Dunnett's post-hoc tests using GraphPad Prism (San Diego, CA).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>E<sub>2</sub> regulates miR-21 expression in MCF-7 breast cancer cells</title><p>Estrogens promote breast tumor development by increasing transcription of protooncogenes and growth factors (<xref ref-type="bibr" rid="B46">46</xref>) and by negatively modulating the expression or functional activity of tumor suppressors (<xref ref-type="bibr" rid="B47">47</xref>). To determine the identity of primary E<sub>2</sub>-regulated miRNAs in estrogen-responsive human breast cancer cells, ER&#x003b1;-positive MCF-7 human breast cancer cells were treated with 10 nM E<sub>2</sub> or EtOH (vehicle control) for 6 h. Among the E<sub>2</sub>-down-regulated miRNAs, we selected miR-21 for further evaluation because miR-21 is an oncomiR and its expression is higher in ER&#x003b1; positive versus negative tumors (<xref ref-type="bibr" rid="B40">40</xref>). Furthermore, no one has examined if E<sub>2</sub> regulates miR-21 expression in breast cancer cells. Q-PCR using the TaqMan primer/probe sets from ABI indicated a &#x0223c;60% reduction in mature miR-21 by E<sub>2</sub> (<xref ref-type="fig" rid="F1">Figure 1</xref>). To determine the mechanism by which E<sub>2</sub> reduces miR-21, MCF-7 cells were pre-incubated with 100 nM ICI 182 780 (ICI, Faslodex), a pure antagonist of ER genomic action (<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>), or 100 nM 4-OHT, the active metabolite of the antiestrogen tamoxifen, and then treated with E<sub>2</sub>. The effect of 4-OHT or ICI alone was also examined. If E<sub>2</sub> represses miR-21 expression by binding ER, then ICI should block the decrease. Because 4-OHT has mixed ER agonist/antagonist activity in a gene- and cell-specific manner, its effect on miR-21 expression could either mimic or oppose the E<sub>2</sub> effect, reflecting its selective ER modulator (SERM) agonist/antagonist activity. ICI reduced ER&#x003b1; protein by &#x0223c;30&#x02013;50% in MCF-7 cells (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 1</ext-link>), but had no effect on basal miR-21 expression (<xref ref-type="fig" rid="F1">Figure 1</xref>). 4-OHT increased miR-21, indicating that 4-OHT opposes E<sub>2</sub>-induced miR-21 repression through ER binding. Since both 4-OHT and ICI relieved E<sub>2</sub> suppression of miR-21, this reduction is ER-mediated. <fig id="F1" position="float"><label>Figure 1.</label><caption><p>E<sub>2</sub> inhibits miR-21 expression. Summary of Q-PCR data on (mature) miR-21 expression. MCF-7 cells were treated with EtOH, 10 nM E<sub>2</sub>, 10 nM PPT (ER&#x003b1;-selective), or 10 nM DPN (ER&#x003b2;-selective) for 6 h. as indicated by the different fills. Where indicated MCF-7 cells were pretreated with 100 nM ICI 182 780 [ICI, an ER antagonist termed a &#x02018;selective ER disrupter&#x02019; (SERD)] or 100 nM 4-OHT for 6 h and then ethanol or 10 nM E<sub>2</sub> was added for an additional 6 h. Values are fold increase compared to EtOH for each miRNA and were calculated as described in &#x02018;Materials and Methods&#x02019; section. Values are the average of three to eight separate experiments &#x000b1; SEM. *Significantly different from the EtOH control, <italic>P</italic> &#x0003c; 0.05. **Significantly different from E<sub>2</sub>, <italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="gkp117f1"/></fig></p><p>Although ER&#x003b1; expression is higher than ER&#x003b2; in MCF-7 cells, both ER subtypes are expressed (<xref ref-type="bibr" rid="B44">44</xref>). To examine the contributions of ER&#x003b1; and ER&#x003b2; to the E<sub>2</sub>-induced reduction in miR-21, MCF-7 cells were treated with 10 nM PPT or 10 nM DPN, concentrations at which each is an ER&#x003b1;- or ER&#x003b2;- selective agonist, respectively (<xref ref-type="bibr" rid="B50">50</xref>). PPT and DPN, like E<sub>2</sub>, reduced miR-21 (<xref ref-type="fig" rid="F1">Figure 1</xref>). E<sub>2</sub> did not regulate miR-21 expression in ER&#x003b1;+/ER&#x003b2;+ T47D cells (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 2</ext-link>), indicating cell-line-specific differences, similar to previous reports that E<sub>2</sub> responses differ between MCF-7 and T47D cells (<xref ref-type="bibr" rid="B51 B52 B53 B54">51&#x02013;54</xref>). Together, these data indicate that both ER&#x003b1; and ER&#x003b2; contribute to miR-21 repression by E<sub>2</sub>.</p></sec><sec><title>Effect of E<sub>2</sub> on miR-21 target gene reporter activity in MCF-7 cells</title><p>The biological activity of miRNAs is primarily mediated by interaction with matching recognition sequences in the 3&#x02032; UTRs of target genes and reducing translation. A &#x0223c;33-bp region from the 3&#x02032;UTR centering on the putative miR-21 miRNA regulatory element (miRNA recognition elements (MREs), also called a &#x02018;seed element&#x02019;, 5&#x02032;-ATAAGCTA-3&#x02032;), and minimally 4 bp flanking this sequence from the six genes listed in <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Table 1</ext-link> were cloned into the 3&#x02032;UTR of pRL-TK <italic>Renilla</italic> reporter plasmid. The pRL-TK-MRE or pRL-TK parental plasmids were transiently transfected into MCF-7 cells with pGL3-pro-luciferase as a control and cells were treated with EtOH or E<sub>2</sub> (<xref ref-type="fig" rid="F2">Figure 2</xref>A and B). If E<sub>2</sub> reduces miR-21, we would expect an increase in the expression of <italic>Renilla</italic> but not Firefly luciferase activity since repression would be relieved. <xref ref-type="fig" rid="F2">Figure 2</xref>C shows that E<sub>2</sub> specifically increased the expression of the <italic>Renilla</italic> luciferase protein from the pRL-TK- transforming growth factor &#x003b2; 1 <italic>(TGFB1)</italic>, Programmed Cell Death 4 (<italic>PDCD4)</italic>, RAS p21 Protein Activator 1 (<italic>RASA1)</italic> and RAS Guanyl Nucleotide-Releasing Protein 1 (<italic>RASGRP1)</italic> reporters in MCF-7 cells, data consistent with miR-21 downregulation by E<sub>2</sub>. In contrast, E<sub>2</sub> did not alter luciferase expression from the putative miR-21 MREs in Cerebral Cavernous Malformations 1 (<italic>CCM1)</italic> or a member of the RAS oncogene family (<italic>RAB6C)</italic>. Thus, the E<sub>2</sub>-mediated decrease in miR-21 expression (<xref ref-type="fig" rid="F1">Figure 1</xref>) resulted in lower amounts of miR-21 available to bind the MRE sequences from the <italic>TGFB1</italic>, <italic>PDCD4</italic>, <italic>RASA1</italic> and <italic>RASGRP1</italic> genes, in turn reducing the targeting of these reporter transcripts for degradation/translational inhibition and thus increasing the amount of <italic>Renilla</italic> protein and luciferase activity. In contrast, the lack of change in <italic>Renilla</italic> activity from <italic>CCM1</italic> and <italic>RAB6C</italic> indicates that the MREs in these genes do not appear to be targets of E<sub>2</sub>-induced reduction of miR-21 expression in MCF-7 cells under our assay conditions. <fig id="F2" position="float"><label>Figure 2.</label><caption><p>Luciferase reporter assay of putative miR-21 target genes and the effect of antisense (AS) to miR-21 on reporter activity. (<bold>A</bold>) Model of transient transfection assays in MCF-7 cells. MCF-7 cells were transiently transfected with pGL3-pro-luciferase and pRL-TK parental or pRL-TK containing putative miR-21 MREs from target genes (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Table 1</ext-link>) cloned in the 3&#x02032;UTR as described in &#x02018;Materials and methods&#x02019; section. Expected results are indicated without E<sub>2</sub> (<bold>A</bold>) and when cells are treated with E<sub>2</sub> (<bold>B</bold>). (<bold>C</bold>) MCF-7 cells were transfected as indicated and treated with EtOH or 10 nM E<sub>2</sub> for 24 h. <italic>Renilla</italic> luciferase was normalized by firefly luciferase to correct for transfection efficiency. Values are the average &#x000b1; SEM of triplicate determinations. *Significantly different from EtOH control, <italic>P</italic> &#x0003c; 0.01. (<bold>D</bold>) MCF-7 cells were transfected with 2&#x02032;-O-Me-antisense-miR-21 (ASmiR-21). <italic>Renilla</italic> luciferase reporter gene expression from the indicated gene MREs was determined and data analyzed as described in &#x02018;Materials and Methods&#x02019; section. The control was a random-sequence 2&#x02032;-O-Me modified RNA (control AS) as described in Materials and methods section. Values are the average &#x000b1; SEM of triplicate determinations. *Significantly different from control AS, <italic>P</italic> &#x0003c; 0.05. (<bold>E</bold>) MCF-7 cells were transfected with the pRL-tk-MREs or FL 3&#x02032;-UTRs as indicated. Indicated cells were co-transfected with ASmiR-21 or a control AS. Cells were treated with EtOH or 10 nM E<sub>2</sub> as indicated for 24 h. Dual luciferase reporter assays were performed and data quantitated as described in &#x02018;Materials and Methods&#x02019; section. Values are the average &#x000b1; SEM of triplicate determinations normalized to EtOH for each construct except that cells transfected with the ASmiR-21 were normalized against the control AS-EtOH value. <sup>a</sup>Significantly different from EtOH control, <italic>P</italic> &#x0003c; 0.01. <sup>b</sup>Significantly different from control AS transfected values, <italic>P</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="gkp117f2"/></fig></p></sec><sec><title>Effect of antisense to miR-21 target gene reporter activity in MCF-7 cells</title><p>If the E<sub>2</sub>-induced increase in <italic>Renilla</italic> luciferase from the MREs of the <italic>TGFB1</italic>, <italic>PDCD4</italic>, <italic>RASA1</italic> and <italic>RASGRP1</italic> genes seen in <xref ref-type="fig" rid="F2">Figure 2</xref>C is due to reduced levels of endogenous miR-21, then transfection of MCF-7 cells with antisense (AS)-miR-21 should have the same effect on luciferase activity. MCF-7 cells were transiently transfected with 2&#x02032;-<italic>O</italic>-Me-anti-miR-21 (AS-miR-21) (<xref ref-type="fig" rid="F2">Figure 2</xref>D). A 92% knockdown of miR-21 expression was achieved (<xref ref-type="fig" rid="F5">Figure 5</xref>A). AS-miR-21 resulted in a significant increase in <italic>Renilla</italic> activity from pRL-TK reporters bearing the miR-21 MREs from the <italic>TGFB1</italic>, <italic>PDCD4</italic>, <italic>RASA1</italic> and <italic>RASGRP1</italic> genes. In contrast, AS-miR-21 did not affect luciferase activity from the putative miR-21 MREs in <italic>CCM1</italic> or <italic>RAB6C</italic> (<xref ref-type="fig" rid="F2">Figure 2</xref>D). These data are in agreement with the E<sub>2</sub> responses (<xref ref-type="fig" rid="F2">Figure 2</xref>C), although E<sub>2</sub> induced higher activity from the <italic>RASA1</italic> reporter compared to the ASmiR-21. Overall, these data indicate that these MREs are bone fide targets of miR-21 regulation.</p></sec><sec><title>MRE and FL 3&#x02032;-UTRs activities of <italic>PDCD4</italic> and <italic>RASA1</italic> in reporter assays in MCF-7 cells</title><p>Since sequences flanking the MRE affect miRNA binding and activity (<xref ref-type="bibr" rid="B55">55</xref>), it is important to compare the effect of E<sub>2</sub> and AS-miR-21 in reporters bearing the MRE versus the FL 3&#x02032;UTR of <italic>PDCD4</italic> and <italic>RASA1</italic> genes (<xref ref-type="fig" rid="F2">Figure 2</xref>E). E<sub>2</sub> induced greater luciferase activity from the FL than the <italic>PDCD4</italic> MRE. AS-miR-21 increased reporter activity more from the MRE than the FL <italic>PDCD4</italic>. The AS-miR-21-induced increase in basal luciferase activity was comparable for the MRE and FL <italic>RASA1</italic> reporters. AS-mR-21 transfection reduced the fold E<sub>2</sub>-induction for the MRE and FL <italic>PDCD4</italic> and <italic>RASA1</italic> reporters. The miR-21 knockdown data are consistent with E<sub>2</sub>-ER downregulation of miR-21 increasing reporter activity.</p></sec><sec><title>Regulation of primary (pri)-miR-21 promoter activity by E<sub>2</sub>, 4-OHT and ICI 182,780 in MCF-7 cells</title><p>miR-21 is located in the 10th intron of the <italic>TMEM49</italic> gene (<xref ref-type="bibr" rid="B56">56</xref>). To test whether E<sub>2</sub> regulates miR-21 gene expression through the &#x0223c;&#x02212;1 kb 5&#x02032;flanking region previously reported to function as a promoter for miR-21 (<xref ref-type="bibr" rid="B45">45</xref>), transient transfection assays were performed using two constructs: pmiR-21s-luc and pmiR-21as-luc, corresponding to the sense (s) and antisense (as) orientations of this &#x0223c;1 kb region cloned in front of the Firefly luciferase gene (<xref ref-type="bibr" rid="B45">45</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>A). The activity from the pmiR-21as-luc reporter was &#x0223c;2% of that of the pmiR-21s-luc construct, indicating orientation-dependent promoter activity. If E<sub>2</sub> represses miR-21 expression by an interaction of ER with the 5&#x02032; promoter, we should detect a decrease in luciferase reporter activity. E<sub>2</sub> reduced luciferase activity &#x0223c;25% whereas 4-OHT increased pmiR-21 activity by &#x0223c;25% (<xref ref-type="fig" rid="F3">Figure 3</xref>A). ICI abrogated the inhibition by E<sub>2</sub>, indicating that ER is responsible for reduction in reporter activity. E<sub>2</sub> did not alter <italic>TMEM49</italic> transcription (<xref ref-type="fig" rid="F3">Figure 3</xref>B). To our knowledge, this is the first examination of the effect of E<sub>2</sub> on <italic>TMEM49</italic> transcription. These data are consistent with the independent regulation of <italic>TMEM49</italic> and miR-21 in HL-60 cells (<xref ref-type="bibr" rid="B56">56</xref>). Overall, these data agree with the direction, although not magnitude, of changes in endogenous miR-21 expression in response to E<sub>2</sub>, 4-OHT and ICI in MCF-7 cells (<xref ref-type="fig" rid="F1">Figure 1</xref>) and indicate that the &#x02212;1 kb promoter of miR-21 mediates in part, the observed reduction in miR-21 expression by E<sub>2</sub>. <fig id="F3" position="float"><label>Figure 3.</label><caption><p>Regulation of miR-21 transcription in MCF-7 cells. (<bold>A</bold>) Effects of E<sub>2</sub>, 4-OHT and ICI 182 780 (ICI) on the primary miR-21 (pri-miR-21) gene promoter in the sense (pmiR-21s-luc) or antisense (as) pmiR-21as-luc orientation. MCF-7 cells were transfected with pri-miR-21s-luc or pri-miR-21as-luc (hatched bars, values were very low) (<xref ref-type="bibr" rid="B45">45</xref>) and <italic>Renilla</italic> luciferase as an internal control. Cells were treated with the indicated concentrations of E<sub>2</sub>, 4-OHT, or ICI for 24 h. Dual luciferase assays were performed and luciferase values were divided by <italic>Renilla</italic> values in the same sample. Values are the average &#x000b1; SEM of triplicate determinations normalized to EtOH for the pmiR-21s-luc construct. *Significantly different from EtOH control, <italic>P</italic> &#x0003c; 0.05. **Significantly different from 4-OHT alone, <italic>P</italic> &#x0003c; 0.05. ***Significantly different from 10 nM E<sub>2</sub>, <italic>P</italic> &#x0003c; 0.05. (<bold>B</bold>) E<sub>2</sub> does not affect <italic>TMEM49</italic> transcription in MCF-7 cells. miR-21 is encoded within the 10th intron of the <italic>TMEM49</italic> gene (<xref ref-type="bibr" rid="B56">56</xref>). MCF-7 cells were treated with EtOH or 10 nM E<sub>2</sub> for 6 h, total RNA was reverse transcribed and Q&#x02013;PCR was performed. <italic>TMEM49</italic> was normalized to 18S. Values are the average &#x000b1; SEM of triplicate determinations normalized to EtOH. (<bold>C</bold>) The E<sub>2</sub>-induced decrease in miR-21 expression in MCF-7 cells is mediated in a primary transcriptional/genomic and secondary estrogen-target-dependent manner. MCF-7 cells were pre-treated with stripped medium or stripped medium containing 10 &#x003bc;g/ml ActD or CHX for 1 h before treatment with vehicle control (EtOH), or 10 nM E<sub>2</sub> for 6 h as described in &#x02018;Materials and Methods&#x02019; section. miR-21 expression was determined using Q-PCR as described in &#x02018;Materials and Methods&#x02019; section. The bar graph summarizes the fold change in miR-21 expression relative to no pretreatment (No pretx)-EtOH-treated cells.</p></caption><graphic xlink:href="gkp117f3"/></fig></p></sec><sec><title>Actinomycin D (ActD) and cycloheximide (CHX) block E<sub>2</sub>-mediated miR-21 expression</title><p>To determine whether the E<sub>2</sub>-mediated reduction in miR-21 expression is a direct effect of ER at the genomic level or requires synthesis of a secondary estrogen-responsive protein, MCF-7 cells were pretreated with the transcriptional inhibitor ActD or the protein synthesis inhibitor CHX prior to EtOH or E<sub>2</sub> treatment (<xref ref-type="fig" rid="F3">Figure 3</xref>C). Pretreatment with ActD and CHX blocked E<sub>2</sub>-mediated miR-21 repression, indicating that E<sub>2</sub>-repression is mediated by both transcriptional (primary genomic) and secondary mechanisms.</p></sec><sec><title>Effect of E<sub>2</sub>, PPT and DPN on endogenous miR-21 target genes in MCF-7 cells</title><p>Since E<sub>2</sub> reduced miR-21 expression in MCF-7 cells and increased the expression of miR-21 target reporter gene activity, the effect of E<sub>2</sub> on the mRNA and protein levels of endogenous miR-21-target genes <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic> was examined by Q-PCR (<xref ref-type="fig" rid="F4">Figure 4</xref>A) and western blot (<xref ref-type="fig" rid="F4">Figure 4</xref>B and C). To determine the relative contribution of the two ER subtypes to these effects, MCF-7 cells were treated with 10 nM PPT or 10 nM DPN, concentrations at which each is an ER&#x003b1;- or ER&#x003b2;-selective agonist, respectively (<xref ref-type="bibr" rid="B50">50</xref>). As expected based on the reporter assay data for <italic>PDCD4</italic> in <xref ref-type="fig" rid="F2">Figure 2</xref>, E<sub>2</sub> increased mRNA (<xref ref-type="fig" rid="F4">Figure 4</xref>A) and protein (<xref ref-type="fig" rid="F4">Figure 4</xref>B and C) levels of <italic>PDCD4</italic>, results reflecting reduced miR-21 levels (<xref ref-type="fig" rid="F1">Figure 1</xref>), thus increased transcript stability. Similar results were observed for <italic>BCL2</italic>. PPT also increased <italic>PDCD4</italic> and <italic>BCL2</italic> mRNA and protein levels, whereas DPN reduced <italic>PDCD4</italic> and increased <italic>BCL2</italic> mRNA levels (<xref ref-type="fig" rid="F4">Figure 4</xref>A) while increasing protein amounts (<xref ref-type="fig" rid="F4">Figure 4</xref>B). E<sub>2</sub>, PPT and DPN increased PTEN protein but not RNA levels (<xref ref-type="fig" rid="F4">Figure 4</xref>A and C), suggesting translational inhibition. Overall, these data indicate roles for both ER&#x003b1; and ER&#x003b2; in mediating the effects of E<sub>2</sub> on miR-21 target gene expression, consistent with results shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. <fig id="F4" position="float"><label>Figure 4.</label><caption><p>Effect of ER ligands on endogenous miR21 target gene mRNA and protein expression in MCF-7 cells. MCF-7 cells were serum-starved for 48 h and then treated with EtOH, 10 nM E<sub>2</sub>, 10 nM PPT (ER&#x003b1; selective), or 10 nM DPN (ER&#x003b2; selective) for 6 h prior to RNA isolation (A) or 24 h prior to WCE preparation (<bold>B</bold>) as described in &#x02018;Materials and methods&#x02019; section. (<bold>A</bold>) Q-PCR was performed for the indicated genes and fold-expression determined compared to EtOH as described in &#x02018;Materials and Methods&#x02019; section. Values are the average of four separate determinations &#x000b1; SEM. (<bold>B</bold>) Western blot for the indicated proteins. The membrane was stripped and reprobed for &#x003b2;-actin for normalization as described in &#x02018;Materials and Methods&#x02019; section. The blot shown is representative of three separate biological replicates. (<bold>C</bold>) Western data are presented as relative to non-treated (No TX) MCF-7 cells. The values in C are the mean &#x000b1; SEM of three separate experiments. *Significantly different from the EtOH value for each protein, <italic>P</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="gkp117f4"/></fig></p></sec><sec><title>AS-miR-21 inhibits endogenous miR-21 target gene protein expression in MCF-7 cells</title><p>To confirm the role of downregulation of miR-21 in the increase in protein expression of Pdcd4, PTEN and Bcl-2, MCF-7 cells were transfected with AS-control and AS-miR-21 plasmids followed by treatment with EtOH, E<sub>2</sub>, PPT and DPN for 24 h. If the ER-ligand-induced reduction in miR-21 causes an increase in target protein expression, then the AS-miR-21 should have the same effect. AS-miR-21 reduced miR-21 by 92% (<xref ref-type="fig" rid="F5">Figure 5</xref>A). Specific knockdown of miR-21, and not miR-125a or miR-30b, was confirmed by Q&#x02013;PCR (<xref ref-type="fig" rid="F5">Figure 5</xref>A). AS-miR-21 significantly increased the basal Pdcd4, PTEN and Bcl-2 protein expression (<xref ref-type="fig" rid="F5">Figure 5</xref>B and C). AS-control did not affect the observed increase in each protein in response to E<sub>2</sub>, PPT and DPN (compare <xref ref-type="fig" rid="F4">Figures 4</xref>B, C and 5B, C). These data indicate that these genes are targets of repression by miR-21. No further increase in protein expression was detected with E<sub>2</sub> or PPT treatment, but DPN significantly increased Pdcd4 and PTEN proteins (<xref ref-type="fig" rid="F5">Figure 5</xref>C). <fig id="F5" position="float"><label>Figure 5.</label><caption><p>A<bold>S</bold>-miR-21 increases the expression of PTEN, PDCD4 and Bcl-2. (<bold>A</bold>) The specificity of AS-miR-21 to decrease miR-21was examined by Q-PCR in parallel with miR-125a and miR-30b as negative controls. MCF-7 cells were not transfected (unTF) or were transfected with AS-control or AS-miR-21 for 48 h prior to RNA harvest. Q-PCR was performed for the indicated miRs. The values are the average of three separate experiments, each run in triplicate, &#x000b1; SD. (<bold>B</bold>) MCF-7 cells were transfected with AS-control or AS-miR-21 for 24 h prior to serum deprivation for 48 h and then 24 h treatment with EtOH, 10 nM E<sub>2</sub>, PPT or DPN, as indicated. WCE were used for western blot for the indicated proteins as described in &#x02018;Materials and methods&#x02019; section. The membrane was stripped and reprobed for &#x003b2;-actin for normalization as described in Materials and Methods section. The blot shown is representative of three separate biological replicates. (<bold>C</bold>) The values graphed are the mean &#x000b1; SEM of the normalized western data (each protein was normalized to &#x003b2;-actin input and then the ratio of each protein/&#x003b2;-actin in the AS-control in EtOH-treated samples was set to one in each experiment) in three separate experiments. *Significantly different from the EtOH AS-control for each protein, <italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="gkp117f5"/></fig></p></sec><sec><title>Effect of ER&#x003b1; knock-down on E<sub>2</sub>-induced endogenous miR-21 target gene expression in MCF-7 cells</title><p>To confirm the role of ER&#x003b1; in the observed decrease in miR-21 and increase in miR-21-target gene expression in response to E<sub>2</sub> and PPT, MCF-7 cells were transfected with siRNA targeting ER&#x003b1; or control siRNA for 48 h and then treated with EtOH, 10 nM E<sub>2</sub>, PPT, or DPN for 6 h. Transfection of MCF-7 cells with siRNA for ER&#x003b1; reduced ER&#x003b1; mRNA expression by &#x0223c;62% (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 3</ext-link>) and ER&#x003b1; protein by 61%. In contrast, ER&#x003b2; protein levels were unaffected (<xref ref-type="fig" rid="F6">Figure 6</xref>A, see also <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 4</ext-link>). siER&#x003b1; blocked the E<sub>2</sub>-induced repression of miR-21 (<xref ref-type="fig" rid="F6">Figure 6</xref>B). Concordantly, knockdown of ER&#x003b1; reduced the E<sub>2</sub>-stimulated expression of miR-21 target genes <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic> (<xref ref-type="fig" rid="F6">Figure 6</xref>C). To confirm these findings at the protein level, western blots were performed using antibodies commercially available for Pdcd4, PTEN and Bcl-2 (<xref ref-type="fig" rid="F6">Figure 6</xref>D). Results confirm that ER&#x003b1; knockdown reduced the E<sub>2</sub>- and PPT-induced protein expression of the miR-21 target genes <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic> to basal levels (<xref ref-type="fig" rid="F6">Figure 6</xref>E). siER&#x003b1; also reduced DPN-stimulated expression of Pdcd4, PTEN and Bcl-2 proteins suggesting that at least part of the DPN response may be ER&#x003b1;-mediated. <fig id="F6" position="float"><label>Figure 6.</label><caption><p>ER&#x003b1;, but not ER&#x003b2;, knockdown inhibits the E<sub>2</sub>-mediated decrease in miR-21 and thus reverses miR-21 target gene expression. (<bold>A</bold>) MCF-7 cells were not transfected (Not TF) or transfected with siControl RNA or siER&#x003b1; as described in &#x02018;Materials and Methods&#x02019; section for 48 h and WCE were analyzed for ER&#x003b1; and ER&#x003b2; by western blot as described in &#x02018;Materials and Methods&#x02019; section. The same membrane was stripped and reprobed for &#x003b2;-actin for normalization. The% ER&#x003b1; knockdown was calculated relative to the Not TF control. (<bold>B</bold>) MCF-7 cells were transfected with siControl RNA or siER&#x003b1; for 48 h prior to treatment with EtOH or 10 nM E<sub>2</sub>, PPT, or DPN for 6 h. RNA and protein were extracted and Q-PCR (<bold>B</bold> and <bold>C</bold>) or western blots (<bold>D</bold> and <bold>E</bold>) were performed for the indicated miR-21 targets as described in &#x02018;Materials and Methods&#x02019; section. The blots shown are representative of three separate biological replicates. The values in (E) are the mean &#x000b1; SEM of three to four separate experiments. (<bold>F</bold>) MCF-7 cells were transfected with siControl RNA or siER&#x003b2; for 48 h prior to treatment with EtOH or 10 nM E<sub>2</sub> for 6 h. MiR-21 expression is the mean fold change &#x000b1; SEM of four samples. Values are mean &#x000b1; SEM. *Significantly different from the EtOH siControl for each protein, <italic>P</italic> &#x0003c; 0.05. **Significantly different from E<sub>2</sub>, PPT or DPN siControl value for that protein, <italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="gkp117f6"/></fig></p></sec><sec><title>Effect of ER&#x003b2; knock-down on miR-21 expression in MCF-7 cells</title><p>To examine ER&#x003b2;'s role in mediating E<sub>2</sub>-suppression of miR-21 transcription, MCF-7 cells were transfected with siRNA targeting ER&#x003b2; or control siRNA for 48 h and then treated with EtOH or 10 nM E<sub>2</sub> for 6 h. siER&#x003b2; reduced ER&#x003b2; mRNA expression by &#x0223c;70% and protein by 64% (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 5A and B</ext-link>). Knockdown of ER&#x003b2; reduced basal miR-21 by 73% and E<sub>2</sub> treatment had no further effect (<xref ref-type="fig" rid="F6">Figure 6</xref>F). siER&#x003b2; resulted in a commensurate increase in basal <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic> mRNA and a loss of E<sub>2</sub>, DPN and PPT-stimulated PDCD4 and BCL2 transcription (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 5C</ext-link> and <xref ref-type="fig" rid="F4">Figure 4</xref>). With ER&#x003b2; knockdown, PPT and DPN increased <italic>PTEN</italic> mRNA (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 5C</ext-link>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Since the oncomiR miR-21 was the most significantly up-regulated miRNA in breast tumor biopsies compared to normal breast tissue (<xref ref-type="bibr" rid="B37">37</xref>) and because estrogen stimulates breast tumorigenesis, the goal of this study was to determine if E<sub>2</sub> regulates the expression of miR-21 in MCF-7 cells as an established human breast cancer model of estrogen responses. To our knowledge, this is the first report that E<sub>2</sub> downregulates miR-21 and thus upregulates the protein expression of miR-21 target genes <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic> in MCF-7 human breast cancer cells. Furthermore, the ability of 4-OHT, ICI and siER&#x003b1; to block the E<sub>2</sub> repression of miR-21 and the subsequent increase in Pdcd4, Pten and Bcl-2 proteins provide a mechanism for the E<sub>2</sub> effect, i.e. through ER&#x003b1; activation. ER&#x003b2; appears to regulate basal miR-21 expression in MCF-7 cells since knockdown of ER&#x003b2; reduced miR-21 expression. ER&#x003b2; represses/opposes ER&#x003b1; transcriptional activity and E<sub>2</sub>-induced cell proliferation (<xref ref-type="bibr" rid="B57 B58 B59 B60 B61">57&#x02013;61</xref>). Stable transfection of MCF-7 cells with ER&#x003b2; inhibited xenograft tumor growth, indicating that ER&#x003b2; is a tumor suppressor (<xref ref-type="bibr" rid="B62">62</xref>). We observed that ER&#x003b2; knock down reduced basal miR-21 and there was no further reduction in miR-21 expression with E<sub>2</sub> treatment. These data appear to indicate a relief of repression of ER&#x003b1;'s inhibition of miR-21 transcription. <xref ref-type="fig" rid="F7">Figure 7</xref> shows a schematic model illustrating ER regulation of miR-21 and miR-21 regulation of its targets. Our results showing that E<sub>2</sub> reduces miR-21 expression in MCF-7 are in agreement with recent reports that E<sub>2</sub> down-regulated miR-21 in endometrial stromal cells (<xref ref-type="bibr" rid="B63">63</xref>) and in the uterus of ovariectomized mice (<xref ref-type="bibr" rid="B64">64</xref>). <fig id="F7" position="float"><label>Figure 7.</label><caption><p>ER regulates miR-21 expression and its downstream targets in a ligand-dependent manner. E<sub>2</sub>-ER (ER&#x003b1; and/or ER&#x003b2;) inhibits miR-21 expression resulting in a loss of repression (indicated by the Xs) of Pdcd4, PTEN and Bcl-2 protein expression. E<sub>2</sub>-ER&#x003b1; directly increases <italic>BCL2</italic> transcription (arrow, +). 4-OHT and ICI block ER-induced inhibition of miR-21 expression. E<sub>2</sub>-ER also regulates the expression of other miRNAs and mRNAs that, in turn, regulate other cellular pathways which impact the expression of <italic>PDCD4</italic>, <italic>PTEN</italic> and <italic>BCL2</italic>.</p></caption><graphic xlink:href="gkp117f7"/></fig></p><p>At the same time, given the established link between estrogen and breast carcinogenesis (<xref ref-type="bibr" rid="B65">65</xref>,<xref ref-type="bibr" rid="B66">66</xref>), one might expect E<sub>2</sub> to upregulate miR-21 rather than inhibit miR-21 as shown here. Likewise, the increase in miR-21 expression by 4-OHT appears to contradict its anticipated anti-tumor role, but is consistent with 4-OHT's gene-specific SERM activity as indicated by its activity opposing E<sub>2</sub>'s inhibition of miR-21 expression. For complex phenotypes including cell proliferation, genes and proteins are up- and down- regulated by a variety of interacting mechanisms that we are only beginning to understand and integrate. Our data are supported by a recent report showing that miR-21 expression was reduced in TAM-resistant MCF-7 cells (<xref ref-type="bibr" rid="B67">67</xref>), a finding likely reflecting the loss of ER-regulated responses in TAM-resistant cells. It is well-established that E<sub>2</sub> and 4-OHT regulate transcription in a gene- and cell-specific manner (<xref ref-type="bibr" rid="B68 B69 B70 B71 B72">68&#x02013;72</xref>) and the findings reported here add miR-21 to the list of ER-regulated genes. We conclude that our apparent &#x02018;contradictory data&#x02019; of E<sub>2</sub> down-regulating and 4-OHT increasing miR-21 expression add unexpected complexity to understanding of E<sub>2</sub> action in breast tumorigenesis.</p><p>The reduction of miR-21 expression in response to E<sub>2</sub> appears to be mediated, in part, by the &#x02212;1kb promoter. However, because the reduction in transcription was only &#x0223c;25% in the reporter assay compared to a &#x0223c;80% reduction by Q-PCR analysis of miR-21 expression, it is possible that additional regions are also important in regulating miR-21 expression in response to E<sub>2</sub>. It has been established that E<sub>2</sub> increases ER&#x003b1; binding to chromosome regions outside gene promoters (<xref ref-type="bibr" rid="B73">73</xref>,<xref ref-type="bibr" rid="B74">74</xref>). Analysis of the miR-21 promoter using TRANSFAC (<ext-link ext-link-type="uri" xlink:href="http://www.gene-regulation.com/">http://www.gene-regulation.com/</ext-link>) identified a non-consensus ERE with a 2-bp spacer: 5&#x02032;-AGCTGAgcTGACC-3&#x02032; located 883-bp upstream of the TATA-binding site. Previous studies showed no binding of ER&#x003b1; to an ERE with a 2-bp spacer <italic>in vitro</italic> (<xref ref-type="bibr" rid="B75">75</xref>). However, in addition to direct ERE binding, ER&#x003b1; regulates gene transcription by tethering to other transcription factors. Genes repressed by E<sub>2</sub>-ER&#x003b1; in MCF-7 cells lack EREs and instead have binding sites for Ikaros (<italic>IKZF1</italic>) and PAX homeobox factors, among others (<xref ref-type="bibr" rid="B76">76</xref>), that are also located in the miR-21 promoter. miR-21 is located in the 3&#x02032;UTR of <italic>TMEM49</italic> located at 17q23.1. Using data from Myles Brown's online database of genomic E<sub>2</sub>-ER&#x003b1;-binding sites in MCF-7 cells from chromatin immunoprecipitation of ER&#x003b1; on-human genome tiled microarray data (ChIP-on-chip) for human chromosome 17 (<xref ref-type="bibr" rid="B73">73</xref>) <ext-link ext-link-type="uri" xlink:href="http://research.dfci.harvard.edu/brownlab/datasets/index.php?dir=ER_MCF7_whole_human_genome/">http://research.dfci.harvard.edu/brownlab/datasets/index.php?dir=ER_MCF7_whole_human_genome/</ext-link>, we found that both E<sub>2</sub>-ER&#x003b1; and RNA polymerase II binding overlap with the 71-bp miR-21 gene (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp117/DC1">Supplementary Figure 6</ext-link>). AP-1 was shown to activate miR-21 transcription by direct interaction with three binding sites in the miR-21 promoter in response to PMA treatment of HL-60 cells (<xref ref-type="bibr" rid="B56">56</xref>). Although both ER&#x003b1; and ER&#x003b2; interact with AP-1 to regulate gene expression, the direction of regulation (up or down) varies depending on the ligand, cell type, chromatin context and neighboring transcription factor-binding events (<xref ref-type="bibr" rid="B77">77</xref>,<xref ref-type="bibr" rid="B78">78</xref>). Here we showed that E<sub>2</sub> did not alter <italic>TMEM49</italic> transcription which supports previous results that <italic>TMEM49</italic> and miR-21 are independently regulated (<xref ref-type="bibr" rid="B56">56</xref>). Further studies will be required to analyze the precise mechanisms mediating E<sub>2</sub> repression of miR-21.</p><p>Both E<sub>2</sub> and AS-miR-21 induced <italic>RASA1</italic> reporter activity; however, the magnitude of luciferase induction was higher with E<sub>2</sub> than AS-miR-21. Although normalized relative luciferase between EtOH versus controlAS transfected cells is an unequal comparison, one possible explanation for this difference is that E<sub>2</sub> alters the expression of other genes or pathways that selectively impact the <italic>RASA1</italic> reporter compared to the other reporters, e.g. <italic>TGFB1</italic> and <italic>PDCD4</italic>, that show similar luciferase activity.</p><p>Our data showing the downregulation of miR-21 by E<sub>2</sub> correlated with upregulation of <italic>PDCD4</italic> RNA and protein (<xref ref-type="fig" rid="F4">Figure 4</xref>B and C) are in agreement with a report that blocking miR-21 using locked nucleic-acid-modified oligonucleotides increased <italic>PDCD4</italic> mRNA and protein in MCF-7 cells (<xref ref-type="bibr" rid="B79">79</xref>). Furthermore, our results in the transient transfection assays indicate that miR-21 regulates <italic>PDCD4</italic> by an MRE in the 3&#x02032;UTR. The conclusion that E<sub>2</sub>-increases <italic>PDCD4</italic> expression through inhibition of miR-21 expression in MCF-7 cells is further supported by data showing that AS-miR-21 inhibited E<sub>2</sub>-induced <italic>Renilla</italic> luciferase activity from the <italic>PDCD4</italic> MRE and 3&#x02032;-UTR in transfected MCF-7 (<xref ref-type="fig" rid="F2">Figure 2</xref>B) and that AS-miR-21 mimics E<sub>2</sub>-induction of Pdcd4 protein (<xref ref-type="fig" rid="F5">Figure 5</xref>C). Our ER&#x003b1; knockdown experiments indicate that ER&#x003b1; is responsible for the E<sub>2</sub>-mediated inhibition of miR-21 expression and regulation of <italic>PDCD4</italic> as well as other miR-21 target genes. The DPN- induced reduction in <italic>PDCD4</italic> mRNA aligns with a report that DPN-activated ER&#x003b2; inhibits the transcription of PPT-activated ER&#x003b1; target genes in human breast cancer cells (<xref ref-type="bibr" rid="B57">57</xref>). The increase seen in Pdcd4 protein after 24 h of DPN treatment may result from a secondary gene effect.</p><p>miR-21 functions as an oncogene and modulates tumorigenicity through regulation of Bcl-2 in MCF-7 cells (<xref ref-type="bibr" rid="B38">38</xref>). Inhibition of miR-21 expression by AS-miR-21 reduced Bcl-2 protein expression and increased apoptosis in MCF-7 cells <italic>in vitro</italic> and in tumor xenografts in mice (<xref ref-type="bibr" rid="B38">38</xref>). Consistent with these findings, our data demonstrate that both E<sub>2</sub> and PPT decrease miR-21 and increase <italic>BCL2</italic> mRNA and protein expression in MCF-7 cells. <italic>BCL2</italic> expression has long been considered a good prognostic marker in breast cancer (<xref ref-type="bibr" rid="B80">80</xref>). DPN increased <italic>BCL2</italic> mRNA and protein expression; likely by ER&#x003b1; activation because E<sub>2</sub> regulates <italic>BCL2</italic> transcription in MCF-7 cells via ER&#x003b1;- Sp1 and AP1 interactions (<xref ref-type="bibr" rid="B81">81</xref>), we can not conclude that the increase in <italic>BCL2</italic> mRNA is due solely to E<sub>2</sub>-mediated decreased miR-21. Further studies will be needed to dissect the relative contributions of multiple ER&#x003b1;-mediated pathways controlling <italic>BCL2</italic> gene expression.</p><p><italic>PTEN</italic> is an important tumor suppressor (<xref ref-type="bibr" rid="B82">82</xref>) that has been identified as a breast cancer susceptibility gene (<xref ref-type="bibr" rid="B83">83</xref>). miR-21 regulates <italic>PTEN</italic> in human hepatocellular cancer cells and tumors (<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B84">84</xref>) but to our knowledge, no one has examined miR-21 regulation of <italic>PTEN</italic> in breast cancer. We found that E<sub>2</sub>, PPT and DPN increased PTEN protein levels without affecting PTEN transcript levels (<xref ref-type="fig" rid="F4">Figure 4</xref>), indicating translational inhibition. Knockdown of ER&#x003b1; by siRNA blocked the E<sub>2</sub>-mediated downregulation of miR-21 and the E<sub>2</sub>-induced increase in <italic>PTEN</italic>, indicating that this effect is mediated via ER&#x003b1;, and commensurate with downregulation of miR-21. With ER&#x003b2; knockdown, PPT and DPN increased <italic>PTEN</italic> mRNA; however, because E<sub>2</sub>, PPT and DPN did not regulate <italic>PTEN</italic> mRNA in MCF-7 cells, it is likely that this increase is mediated by the loss of the expression of another <italic>PTEN</italic> transcriptional repressor with ER&#x003b2; knockdown. Our data contradict a previous report showing no alteration of <italic>PTEN</italic> expression in MCF-7 cells treated with 100 nM E<sub>2</sub> for 24 h (<xref ref-type="bibr" rid="B85">85</xref>). This difference may be due to the lower, physiologically relevant E<sub>2</sub> concentration and shorter treatment time used here.</p><p>In summary, we report for the first time that miR-21 is down-regulated in response to E<sub>2</sub> in an ER&#x003b1;-dependent manner and that ER&#x003b2; regulates basal miR-21 expression. Furthermore, this inhibition correlates with up-regulation of miR-21 targets: PDCD4, PTEN and Bcl-2. The identification of miR-21 as a miRNA regulated by ER may open new avenues for potential therapeutic intervention in breast cancer treatment.</p></sec><sec><title>FUNDING</title><p><grant-sponsor>National Institutes of Health</grant-sponsor><grant-num>R21 CA124811</grant-num> and an Intramural Research Incentive Grant from the Office of the Senior Vice President for Research [to C.M.K.]. Pre-doctoral fellowship from National Institutes of Environmental Health Sciences T32 ES011564 [to K.A.R.]. Funding for open access charge: <grant-sponsor>National Institutes of Health</grant-sponsor><grant-num>R21 CA124811</grant-num> to C.M.K.</p><p><italic>Conflict of interest statement</italic>. None declared.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplementary Data]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="gkp117_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="gkp117_nar-02485-s-2008-File003.doc"/><media xlink:role="associated-file" mimetype="application" mime-subtype="vnd.ms-powerpoint" xlink:href="gkp117_nar-02485-s-2008-File004.ppt"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>We thank Dr Bryan R. Cullen for providing the pri-miR-21 promoter luciferase reporter constructs used in this study. We thank Jeremy S. Harbour and Abirami Krishnasamy for helping with western blots. We thank Drs Barbara J. Clark and Nancy C. Martin for their comments to improve this manuscript. Thanks to Drs Myles Brown and Mathieu Lupien from Harvard University and Dr Ted Kalbflesich (UofL) for their help with the genome analysis for Supplementary Figure 6.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kushner</surname><given-names>PJ</given-names></name><name><surname>Agard</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>WJ</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name><name><surname>Schiau</surname><given-names>A</given-names></name><name><surname>Uht</surname><given-names>R</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Greene</surname><given-names>G</given-names></name></person-group><article-title>Oestrogen receptor function at classical and alternative response elements</article-title><source>Novartis Found Symp.</source><year>2000</year><volume>230</volume><fpage>20</fpage><lpage>26</lpage><comment>discussion 27&#x02013;40</comment><pub-id pub-id-type="pmid">10965500</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Samudio</surname><given-names>I</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Transcriptional activation of thymidylate synthase by 17beta-estradiol in MCF-7 human breast cancer cells</article-title><source>Endocrinology</source><year>2000</year><volume>141</volume><fpage>2439</fpage><lpage>2449</lpage><pub-id pub-id-type="pmid">10875244</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>Lanz</surname><given-names>RB</given-names></name><name><surname>O'Malley</surname><given-names>BW</given-names></name></person-group><article-title>Nuclear receptor coregulators: cellular and molecular biology</article-title><source>Endocr. Rev.</source><year>1999</year><volume>20</volume><fpage>321</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">10368774</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cvoro</surname><given-names>A</given-names></name><name><surname>Tzagarakis-Foster</surname><given-names>C</given-names></name><name><surname>Tatomer</surname><given-names>D</given-names></name><name><surname>Paruthiyil</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>MS</given-names></name><name><surname>Leitman</surname><given-names>DC</given-names></name></person-group><article-title>Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression</article-title><source>Mol. Cell</source><year>2006</year><volume>21</volume><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">16483936</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ER</given-names></name></person-group><article-title>Integration of the extranuclear and nuclear actions of estrogen</article-title><source>Mol. Endocrinol.</source><year>2005</year><volume>19</volume><fpage>1951</fpage><lpage>1959</lpage><pub-id pub-id-type="pmid">15705661</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>CS</given-names></name><name><surname>Alyea</surname><given-names>RA</given-names></name><name><surname>Jeng</surname><given-names>YJ</given-names></name><name><surname>Kochukov</surname><given-names>MY</given-names></name></person-group><article-title>Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues</article-title><source>Mol. Cell Endocrinol.</source><year>2007</year><volume>274</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17601655</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Redmond</surname><given-names>CK</given-names></name><name><surname>Kavanah</surname><given-names>M</given-names></name><name><surname>Cronin</surname><given-names>WM</given-names></name><name><surname>Vogel</surname><given-names>V</given-names></name><name><surname>Robidoux</surname><given-names>A</given-names></name><name><surname>Dimitrov</surname><given-names>N</given-names></name><name><surname>Atkins</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study</article-title><source>J. Natl Cancer Inst.</source><year>1998</year><volume>90</volume><fpage>1371</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">9747868</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis-Wambi</surname><given-names>JS</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs)</article-title><source>Breast Dis.</source><year>2005</year><volume>24</volume><fpage>93</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">16917142</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>A</given-names></name></person-group><article-title>New developments in the treatment of postmenopausal breast cancer</article-title><source>Trends Endocrinol. Met.</source><year>2005</year><volume>16</volume><fpage>420</fpage><lpage>428</lpage></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zamore</surname><given-names>PD</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name></person-group><article-title>Ribo-gnome: the big world of small RNAs</article-title><source>Science</source><year>2005</year><volume>309</volume><fpage>1519</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">16141061</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Principles of micro-RNA production and maturation</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>6156</fpage><lpage>6162</lpage><pub-id pub-id-type="pmid">17028594</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couzin</surname><given-names>J</given-names></name></person-group><article-title>Genetics. Erasing microRNAs reveals their powerful punch</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>530</fpage><pub-id pub-id-type="pmid">17463259</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuellar</surname><given-names>TL</given-names></name><name><surname>McManus</surname><given-names>MT</given-names></name></person-group><article-title>MicroRNAs and endocrine biology</article-title><source>J. Endocrinol.</source><year>2005</year><volume>187</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">16423811</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Steitz</surname><given-names>JA</given-names></name></person-group><article-title>Switching from repression to activation: microRNAs can up-regulate translation</article-title><source>Science</source><year>2007</year><volume>318</volume><fpage>1931</fpage><lpage>1934</lpage><pub-id pub-id-type="pmid">18048652</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>HK</given-names></name><name><surname>Griffiths-Jones</surname><given-names>S</given-names></name><name><surname>Enright</surname><given-names>AJ</given-names></name></person-group><article-title>Genomic analysis of human microRNA transcripts</article-title><source>Proc. Natl Acad. Sci.</source><year>2007</year><volume>104</volume><fpage>17719</fpage><lpage>17724</lpage><pub-id pub-id-type="pmid">17965236</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Liu</surname><given-names>C-G</given-names></name><name><surname>Ambs</surname><given-names>S</given-names></name><name><surname>Cimmino</surname><given-names>A</given-names></name><name><surname>Petrocca</surname><given-names>F</given-names></name><name><surname>Visone</surname><given-names>R</given-names></name><name><surname>Iorio</surname><given-names>M</given-names></name><name><surname>Roldo</surname><given-names>C</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><etal/></person-group><article-title>A microRNA expression signature of human solid tumors defines cancer gene targets</article-title><source>Proc. Natl Acad. Sci</source><year>2006</year><volume>103</volume><fpage>2257</fpage><lpage>2261</lpage><pub-id pub-id-type="pmid">16461460</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Greshock</surname><given-names>J</given-names></name><name><surname>Megraw</surname><given-names>MS</given-names></name><name><surname>Giannakakis</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Naylor</surname><given-names>TL</given-names></name><name><surname>Barchetti</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>MR</given-names></name><etal/></person-group><article-title>microRNAs exhibit high frequency genomic alterations in human cancer</article-title><source>PNAS</source><year>2006</year><volume>103</volume><fpage>9136</fpage><lpage>9141</lpage><pub-id pub-id-type="pmid">16754881</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JA</given-names></name><name><surname>Krichevsky</surname><given-names>AM</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name></person-group><article-title>MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>6029</fpage><lpage>6033</lpage><pub-id pub-id-type="pmid">16024602</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>SM</given-names></name></person-group><article-title>MicroRNAs as oncogenes</article-title><source>Curr. Opin. Genet. Dev.</source><year>2005</year><volume>16</volume><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16361094</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashita</surname><given-names>Y</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Tatematsu</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Yanagisawa</surname><given-names>K</given-names></name><name><surname>Tomida</surname><given-names>S</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>9628</fpage><lpage>9632</lpage><pub-id pub-id-type="pmid">16266980</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>MV</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>C-G</given-names></name><name><surname>Veronese</surname><given-names>A</given-names></name><name><surname>Spizzo</surname><given-names>R</given-names></name><name><surname>Sabbioni</surname><given-names>S</given-names></name><name><surname>Magri</surname><given-names>E</given-names></name><name><surname>Pedriali</surname><given-names>M</given-names></name><name><surname>Fabbri</surname><given-names>M</given-names></name><name><surname>Campiglio</surname><given-names>M</given-names></name><etal/></person-group><article-title>MicroRNA gene expression deregulation in human breast cancer</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>7065</fpage><lpage>7070</lpage><pub-id pub-id-type="pmid">16103053</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Gusev</surname><given-names>Y</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Real-time expression profiling of microRNA precursors in human cancer cell lines</article-title><source>Nucleic Acids Res.</source><year>2005</year><volume>33</volume><fpage>5394</fpage><lpage>5403</lpage><pub-id pub-id-type="pmid">16192569</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SM</given-names></name><name><surname>Grosshans</surname><given-names>H</given-names></name><name><surname>Shingara</surname><given-names>J</given-names></name><name><surname>Byrom</surname><given-names>M</given-names></name><name><surname>Jarvis</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Labourier</surname><given-names>E</given-names></name><name><surname>Reinert</surname><given-names>KL</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><article-title>RAS is regulated by the let-7 microRNA family</article-title><source>Cell</source><year>2005</year><volume>120</volume><fpage>635</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">15766527</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diederichs</surname><given-names>S</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>6097</fpage><lpage>6104</lpage><pub-id pub-id-type="pmid">16778182</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>GK</given-names></name><name><surname>Mattie</surname><given-names>MD</given-names></name><name><surname>Berger</surname><given-names>CE</given-names></name><name><surname>Benz</surname><given-names>SC</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name></person-group><article-title>Rapid alteration of microRNA levels by histone deacetylase inhibition</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>1277</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">16452179</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>JM</given-names></name><name><surname>Newman</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Morin-Kensicki</surname><given-names>EM</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Hammond</surname><given-names>SM</given-names></name></person-group><article-title>Extensive post-transcriptional regulation of microRNAs and its implications for cancer</article-title><source>Genes Dev.</source><year>2006</year><volume>20</volume><fpage>2202</fpage><lpage>2207</lpage><pub-id pub-id-type="pmid">16882971</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>BD</given-names></name><name><surname>Furneaux</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>BA</given-names></name></person-group><article-title>The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-{alpha} (ER{alpha}) and represses ER{alpha} messenger RNA and protein expression in breast cancer cell lines</article-title><source>Mol. Endocrinol.</source><year>2007</year><volume>21</volume><fpage>1132</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">17312270</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blenkiron</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>LD</given-names></name><name><surname>Thorne</surname><given-names>NP</given-names></name><name><surname>Spiteri</surname><given-names>I</given-names></name><name><surname>Chin</surname><given-names>SF</given-names></name><name><surname>Dunning</surname><given-names>MJ</given-names></name><name><surname>Barbosa-Morais</surname><given-names>NL</given-names></name><name><surname>Teschendorff</surname><given-names>AE</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><etal/></person-group><article-title>MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype</article-title><source>Genome Biol.</source><year>2007</year><volume>8</volume><fpage>R214</fpage><pub-id pub-id-type="pmid">17922911</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaur</surname><given-names>A</given-names></name><name><surname>Jewell</surname><given-names>DA</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Ridzon</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Ambros</surname><given-names>VR</given-names></name><name><surname>Israel</surname><given-names>MA</given-names></name></person-group><article-title>Characterization of microRNA expression levels and their biological correlates in human cancer cell lines</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>2456</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">17363563</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannakakis</surname><given-names>A</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Sandaltzopoulos</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>miRNA genetic alterations in human cancers</article-title><source>Exp. Opin. Biol. Ther.</source><year>2007</year><volume>7</volume><fpage>1375</fpage><lpage>1386</lpage></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gramantieri</surname><given-names>L</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Fornari</surname><given-names>F</given-names></name><name><surname>Veronese</surname><given-names>A</given-names></name><name><surname>Sabbioni</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C-G</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Giovannini</surname><given-names>C</given-names></name><name><surname>Ferrazzi</surname><given-names>E</given-names></name><name><surname>Grazi</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>6092</fpage><lpage>6099</lpage><pub-id pub-id-type="pmid">17616664</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurteau</surname><given-names>GJ</given-names></name><name><surname>Carlson</surname><given-names>JA</given-names></name><name><surname>Spivack</surname><given-names>SD</given-names></name><name><surname>Brock</surname><given-names>GJ</given-names></name></person-group><article-title>Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>7972</fpage><lpage>7976</lpage><pub-id pub-id-type="pmid">17804704</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>Esquela-Kerscher</surname><given-names>A</given-names></name><name><surname>Stefani</surname><given-names>G</given-names></name><name><surname>Byrom</surname><given-names>M</given-names></name><name><surname>Kelnar</surname><given-names>K</given-names></name><name><surname>Ovcharenko</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shelton</surname><given-names>J</given-names></name><name><surname>Shingara</surname><given-names>J</given-names></name><etal/></person-group><article-title>The let-7 microRNA represses cell proliferation pathways in human cells</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>7713</fpage><lpage>7722</lpage><pub-id pub-id-type="pmid">17699775</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lujambio</surname><given-names>A</given-names></name><name><surname>Ropero</surname><given-names>S</given-names></name><name><surname>Ballestar</surname><given-names>E</given-names></name><name><surname>Fraga</surname><given-names>MF</given-names></name><name><surname>Cerrato</surname><given-names>C</given-names></name><name><surname>Setien</surname><given-names>F</given-names></name><name><surname>Casado</surname><given-names>S</given-names></name><name><surname>Suarez-Gauthier</surname><given-names>A</given-names></name><name><surname>Sanchez-Cespedes</surname><given-names>M</given-names></name><name><surname>Gitt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic unmasking of an epigenetically silenced microRNA in human cancer cells</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>1424</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">17308079</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Henson</surname><given-names>R</given-names></name><name><surname>Wehbe-Janek</surname><given-names>H</given-names></name><name><surname>Ghoshal</surname><given-names>K</given-names></name><name><surname>Jacob</surname><given-names>ST</given-names></name><name><surname>Patel</surname><given-names>T</given-names></name></person-group><article-title>MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer</article-title><source>Gastroenterology</source><year>2007</year><volume>133</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17681183</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>MicroRNAs in biological processes and carcinogenesis</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17028302</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sempere</surname><given-names>LF</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Silahtaroglu</surname><given-names>A</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Heath</surname><given-names>CV</given-names></name><name><surname>Schwartz</surname><given-names>G</given-names></name><name><surname>Wells</surname><given-names>W</given-names></name><name><surname>Kauppinen</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>CN</given-names></name></person-group><article-title>Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>11612</fpage><lpage>11620</lpage><pub-id pub-id-type="pmid">18089790</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>ML</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Mo</surname><given-names>YY</given-names></name></person-group><article-title>miR-21-mediated tumor growth</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2799</fpage><lpage>2803</lpage><pub-id pub-id-type="pmid">17072344</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Chew</surname><given-names>K</given-names></name><name><surname>Dairkee</surname><given-names>SH</given-names></name><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Eppenberger</surname><given-names>U</given-names></name><name><surname>Eppenberger-Castori</surname><given-names>S</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name></person-group><article-title>Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer</article-title><source>BMC Cancer</source><year>2007</year><volume>7</volume><fpage>59</fpage><pub-id pub-id-type="pmid">17407600</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattie</surname><given-names>MD</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name><name><surname>Bowers</surname><given-names>J</given-names></name><name><surname>Sensinger</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>GK</given-names></name><name><surname>Fedele</surname><given-names>V</given-names></name><name><surname>Ginzinger</surname><given-names>D</given-names></name><name><surname>Getts</surname><given-names>R</given-names></name><name><surname>Haqq</surname><given-names>C</given-names></name></person-group><article-title>Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies</article-title><source>Mol. Cancer</source><year>2006</year><volume>5</volume><fpage>24</fpage><pub-id pub-id-type="pmid">16784538</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gusev</surname><given-names>Y</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name><name><surname>Lerner</surname><given-names>M</given-names></name><name><surname>Postier</surname><given-names>R</given-names></name><name><surname>Brackett</surname><given-names>D</given-names></name></person-group><article-title>Computational analysis of biological functions and pathways collectively targeted by co-expressed microRNAs in cancer</article-title><source>BMC Bioinformatics</source><year>2007</year><volume>8 (Suppl. 7)</volume><fpage>S16</fpage><pub-id pub-id-type="pmid">18047715</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hossain</surname><given-names>A</given-names></name><name><surname>Kuo</surname><given-names>MT</given-names></name><name><surname>Saunders</surname><given-names>GF</given-names></name></person-group><article-title>Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA</article-title><source>Mol. Cell Biol.</source><year>2006</year><volume>26</volume><fpage>8191</fpage><lpage>8201</lpage><pub-id pub-id-type="pmid">16940181</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Stribinskis</surname><given-names>V</given-names></name><name><surname>Klinge</surname><given-names>CM</given-names></name><name><surname>Ramos</surname><given-names>KS</given-names></name><name><surname>Colburn</surname><given-names>NH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>4373</fpage><lpage>4379</lpage><pub-id pub-id-type="pmid">18372920</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattingly</surname><given-names>KA</given-names></name><name><surname>Ivanova</surname><given-names>MM</given-names></name><name><surname>Riggs</surname><given-names>KA</given-names></name><name><surname>Wickramasinghe</surname><given-names>NS</given-names></name><name><surname>Barch</surname><given-names>MJ</given-names></name><name><surname>Klinge</surname><given-names>CM</given-names></name></person-group><article-title>Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis</article-title><source>Mol. Endocrinol.</source><year>2008</year><volume>22</volume><fpage>609</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">18048642</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Hagedorn</surname><given-names>CH</given-names></name><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><article-title>Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs</article-title><source>RNA</source><year>2004</year><volume>10</volume><fpage>1957</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">15525708</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>HP</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name></person-group><article-title>Potential benefits of estrogens and progestogens on breast cancer</article-title><source>Int. J. Fertil. Womens Med.</source><year>1998</year><volume>43</volume><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">9920536</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deroo</surname><given-names>BJ</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name></person-group><article-title>Estrogen receptors and human disease</article-title><source>J. Clin. Invest.</source><year>2006</year><volume>116</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">16511588</pub-id></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijayaratne</surname><given-names>AL</given-names></name><name><surname>Nagel</surname><given-names>SC</given-names></name><name><surname>Paige</surname><given-names>LA</given-names></name><name><surname>Christensen</surname><given-names>DJ</given-names></name><name><surname>Norris</surname><given-names>JD</given-names></name><name><surname>Fowlkes</surname><given-names>DM</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Comparative analyses of mechanistic differences among antiestrogens</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>5828</fpage><lpage>5840</lpage><pub-id pub-id-type="pmid">10579349</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijayaratne</surname><given-names>AL</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>35684</fpage><lpage>35692</lpage><pub-id pub-id-type="pmid">11473106</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>WR</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>Barnett</surname><given-names>DH</given-names></name><name><surname>Petz</surname><given-names>LN</given-names></name><name><surname>Katzenellenbogen</surname><given-names>JA</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name></person-group><article-title>Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression</article-title><source>Mol. Cell Endocrinol.</source><year>2003</year><volume>206</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12943986</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>McDougal</surname><given-names>A</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>1998</year><volume>67</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">10030690</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>KA</given-names></name><name><surname>Thompson</surname><given-names>LU</given-names></name></person-group><article-title>Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation</article-title><source>Breast Cancer Res. Treat</source><year>2003</year><volume>81</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">14620916</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurd</surname><given-names>C</given-names></name><name><surname>Dinda</surname><given-names>S</given-names></name><name><surname>Khattree</surname><given-names>N</given-names></name><name><surname>Moudgil</surname><given-names>VK</given-names></name></person-group><article-title>Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>1067</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">10023683</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zampieri</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>P</given-names></name><name><surname>Ruff</surname><given-names>P</given-names></name><name><surname>Arbuthnot</surname><given-names>P</given-names></name></person-group><article-title>Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells</article-title><source>Anticancer Res.</source><year>2002</year><volume>22</volume><fpage>2253</fpage><lpage>2259</lpage><pub-id pub-id-type="pmid">12174911</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Farh</surname><given-names>KK-H</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNA targeting specificity in mammals: determinants beyond seed pairing</article-title><source>Mol. Cell</source><year>2007</year><volume>27</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">17612493</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Minoguchi</surname><given-names>S</given-names></name><name><surname>Yamamichi</surname><given-names>N</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Iba</surname><given-names>H</given-names></name></person-group><article-title>miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism</article-title><source>J. Mol. Biol.</source><year>2008</year><volume>378</volume><fpage>492</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">18384814</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotoca Covaleda</surname><given-names>AM</given-names></name><name><surname>van den Berg</surname><given-names>H</given-names></name><name><surname>Vervoort</surname><given-names>J</given-names></name><name><surname>van der Saag</surname><given-names>P</given-names></name><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Gustafsson</surname><given-names>J-A</given-names></name><name><surname>Rietjens</surname><given-names>I</given-names></name><name><surname>Murk</surname><given-names>AJ</given-names></name></person-group><article-title>Influence of cellular ER{alpha}/ER{beta} ratio on the ER{alpha}-agonist induced proliferation of human T47D breast cancer cells</article-title><source>Toxicol. Sci.</source><year>2008</year><volume>105</volume><fpage>303</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">18644836</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Li Kong</surname><given-names>S</given-names></name><name><surname>Kietz</surname><given-names>S</given-names></name><name><surname>Thomsen</surname><given-names>JS</given-names></name><name><surname>Tee</surname><given-names>JB</given-names></name><name><surname>Vega</surname><given-names>VB</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer</article-title><source>Breast Cancer Res.</source><year>2007</year><volume>9</volume><fpage>R25</fpage><pub-id pub-id-type="pmid">17428314</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>J</given-names></name><name><surname>Wihlen</surname><given-names>B</given-names></name><name><surname>Tujague</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Gustafsson</surname><given-names>J-A</given-names></name></person-group><article-title>Estrogen receptor (ER) {beta} modulates ER{alpha}-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters</article-title><source>Mol. Endocrinol.</source><year>2006</year><volume>20</volume><fpage>534</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">16293641</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helguero</surname><given-names>LA</given-names></name><name><surname>Faulds</surname><given-names>MH</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name><name><surname>Haldosen</surname><given-names>LA</given-names></name></person-group><article-title>Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>6605</fpage><lpage>6616</lpage><pub-id pub-id-type="pmid">16007178</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Hartman</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>JS</given-names></name><name><surname>Kietz</surname><given-names>S</given-names></name><name><surname>Wimalasena</surname><given-names>J</given-names></name><name><surname>Gustafsson</surname><given-names>J-A</given-names></name></person-group><article-title>Estrogen receptor {beta} inhibits 17{beta}-estradiol-stimulated proliferation of the breast cancer cell line T47D</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>1566</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">14745018</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>D</given-names></name><name><surname>Gill</surname><given-names>JH</given-names></name><name><surname>Fichtner</surname><given-names>I</given-names></name></person-group><article-title>Loss of tumourigenicity of stably ER[beta]-transfected MCF-7 breast cancer cells</article-title><source>Mol. Cell Endocrinol.</source><year>2007</year><volume>274</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">17597290</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Toloubeydokhti</surname><given-names>T</given-names></name><name><surname>Chegini</surname><given-names>N</given-names></name></person-group><article-title>The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression</article-title><source>Mol. Hum. Reprod.</source><year>2007</year><volume>13</volume><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">17766684</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S-J</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>J-L</given-names></name><name><surname>Zhao</surname><given-names>Z-A</given-names></name><name><surname>Yu</surname><given-names>Y-S</given-names></name><name><surname>Su</surname><given-names>R-W</given-names></name><name><surname>Ma</surname><given-names>X-H</given-names></name><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Z-M</given-names></name></person-group><article-title>MicroRNA expression and regulation in mouse uterus during embryo implantation</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>23473</fpage><lpage>23484</lpage><pub-id pub-id-type="pmid">18556655</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Fernandez</surname><given-names>SV</given-names></name><name><surname>Russo</surname><given-names>PA</given-names></name><name><surname>Fernbaugh</surname><given-names>R</given-names></name><name><surname>Sheriff</surname><given-names>FS</given-names></name><name><surname>Lareef</surname><given-names>HM</given-names></name><name><surname>Garber</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>IH</given-names></name></person-group><article-title>17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells</article-title><source>FASEB J.</source><year>2006</year><volume>20</volume><fpage>1622</fpage><lpage>1634</lpage><pub-id pub-id-type="pmid">16873885</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Tahin</surname><given-names>Q</given-names></name><name><surname>Lareef</surname><given-names>MH</given-names></name><name><surname>Hu</surname><given-names>YF</given-names></name><name><surname>Russo</surname><given-names>IH</given-names></name></person-group><article-title>Neoplastic transformation of human breast epithelial cells by estrogens and chemical carcinogens</article-title><source>Environ. Mol. Mutagen.</source><year>2002</year><volume>39</volume><fpage>254</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">11921196</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>TE</given-names></name><name><surname>Ghoshal</surname><given-names>K</given-names></name><name><surname>Ramaswamy</surname><given-names>B</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Datta</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>CL</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Majumder</surname><given-names>S</given-names></name></person-group><article-title>MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(Kip1)</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>29897</fpage><lpage>29903</lpage><pub-id pub-id-type="pmid">18708351</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frasor</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>EC</given-names></name><name><surname>Komm</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>C-Y</given-names></name><name><surname>Vega</surname><given-names>VB</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name></person-group><article-title>Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>7334</fpage><lpage>7340</lpage><pub-id pub-id-type="pmid">16849584</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frasor</surname><given-names>J</given-names></name><name><surname>Danes</surname><given-names>JM</given-names></name><name><surname>Komm</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Lyttle</surname><given-names>CR</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name></person-group><article-title>Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype</article-title><source>Endocrinology</source><year>2003</year><volume>144</volume><fpage>4562</fpage><lpage>4574</lpage><pub-id pub-id-type="pmid">12959972</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frasor</surname><given-names>J</given-names></name><name><surname>Stossi</surname><given-names>F</given-names></name><name><surname>Danes</surname><given-names>JM</given-names></name><name><surname>Komm</surname><given-names>B</given-names></name><name><surname>Lyttle</surname><given-names>CR</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name></person-group><article-title>Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>1522</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">14973112</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levenson</surname><given-names>AS</given-names></name><name><surname>Svoboda</surname><given-names>KM</given-names></name><name><surname>Pease</surname><given-names>KM</given-names></name><name><surname>Kaiser</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Simons</surname><given-names>LA</given-names></name><name><surname>Jovanovic</surname><given-names>BD</given-names></name><name><surname>Dyck</surname><given-names>PA</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>4419</fpage><lpage>4426</lpage><pub-id pub-id-type="pmid">12154049</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vendrell</surname><given-names>JA</given-names></name><name><surname>Bieche</surname><given-names>I</given-names></name><name><surname>Desmetz</surname><given-names>C</given-names></name><name><surname>Badia</surname><given-names>E</given-names></name><name><surname>Tozlu</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Nicolas</surname><given-names>JC</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>PA</given-names></name></person-group><article-title>Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines</article-title><source>Endocr. Relat. Cancer</source><year>2005</year><volume>12</volume><fpage>75</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15788640</pub-id></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Geistlinger</surname><given-names>TR</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Brodsky</surname><given-names>AS</given-names></name><name><surname>Keeton</surname><given-names>EK</given-names></name><name><surname>Fertuck</surname><given-names>KC</given-names></name><name><surname>Hall</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Genome-wide analysis of estrogen receptor binding sites</article-title><source>Nat. Genet.</source><year>2006</year><volume>38</volume><fpage>1289</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">17013392</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y-S</given-names></name><name><surname>Garcia-Bassets</surname><given-names>I</given-names></name><name><surname>Hutt</surname><given-names>KR</given-names></name><name><surname>Cheng</surname><given-names>CS</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Bibikova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sensitive ChIP-DSL technology reveals an extensive estrogen receptor {alpha}-binding program on human gene promoters</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>4852</fpage><lpage>4857</lpage><pub-id pub-id-type="pmid">17360330</pub-id></citation></ref><ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>LB</given-names></name><name><surname>Peale</surname><given-names>FV</given-names><suffix>Jr</suffix></name><name><surname>Klinge</surname><given-names>CM</given-names></name><name><surname>Bambara</surname><given-names>RA</given-names></name><name><surname>Zain</surname><given-names>S</given-names></name><name><surname>Hilf</surname><given-names>R</given-names></name></person-group><article-title>A microtiter well assay for quantitative measurement of estrogen receptor binding to estrogen-responsive elements</article-title><source>Mol. Endocrinol.</source><year>1990</year><volume>4</volume><fpage>1027</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">2284005</pub-id></citation></ref><ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bourdeau</surname><given-names>V</given-names></name><name><surname>Deschenes</surname><given-names>J</given-names></name><name><surname>Laperriere</surname><given-names>D</given-names></name><name><surname>Aid</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>JH</given-names></name><name><surname>Mader</surname><given-names>S</given-names></name></person-group><article-title>Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells</article-title><source>Nucleic Acids Res.</source><year>2008</year><volume>36</volume><fpage>76</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17986456</pub-id></citation></ref><ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>M</given-names></name><name><surname>Galluzzo</surname><given-names>P</given-names></name><name><surname>Ascenzi</surname><given-names>P</given-names></name></person-group><article-title>Estrogen signaling multiple pathways to impact gene transcription</article-title><source>Curr. Genomics</source><year>2006</year><volume>7</volume><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">18369406</pub-id></citation></ref><ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safe</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name></person-group><article-title>Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways</article-title><source>J. Mol. Endocrinol.</source><year>2008</year><volume>41</volume><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">18772268</pub-id></citation></ref><ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>LB</given-names></name><name><surname>Christoffersen</surname><given-names>NR</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Lindow</surname><given-names>M</given-names></name><name><surname>Krogh</surname><given-names>A</given-names></name><name><surname>Lund</surname><given-names>AH</given-names></name></person-group><article-title>Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">17991735</pub-id></citation></ref><ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schorr</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Krajewski</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Furth</surname><given-names>PA</given-names></name></person-group><article-title>Bcl-2 gene family and related proteins in mammary gland involution and breast cancer</article-title><source>J. Mammary Gland Biol. Neoplasia</source><year>1999</year><volume>4</volume><fpage>153</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">10426394</pub-id></citation></ref><ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Stoner</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Harigai</surname><given-names>M</given-names></name><name><surname>Samudio</surname><given-names>I</given-names></name><name><surname>Kladde</surname><given-names>MP</given-names></name><name><surname>Vyhlidal</surname><given-names>C</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>32099</fpage><lpage>32107</lpage><pub-id pub-id-type="pmid">10542244</pub-id></citation></ref><ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ross</surname><given-names>AH</given-names></name></person-group><article-title>Why is PTEN an important tumor suppressor?</article-title><source>J. Cell Biochem.</source><year>2007</year><volume>102</volume><fpage>1368</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">17972252</pub-id></citation></ref><ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradbury</surname><given-names>AR</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name></person-group><article-title>Genetic susceptibility to breast cancer</article-title><source>Rev. Endocr. Metab. Disord.</source><year>2007</year><volume>8</volume><fpage>255</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">17508290</pub-id></citation></ref><ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Rasheed</surname><given-names>SAK</given-names></name><name><surname>Nikolova</surname><given-names>DA</given-names></name><name><surname>Leupold</surname><given-names>JH</given-names></name><name><surname>Colburn</surname><given-names>NH</given-names></name><name><surname>Post</surname><given-names>S</given-names></name><name><surname>Allgayer</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>2128</fpage><lpage>2136</lpage><pub-id pub-id-type="pmid">17968323</pub-id></citation></ref><ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonofiglio</surname><given-names>D</given-names></name><name><surname>Gabriele</surname><given-names>S</given-names></name><name><surname>Aquila</surname><given-names>S</given-names></name><name><surname>Catalano</surname><given-names>S</given-names></name><name><surname>Gentile</surname><given-names>M</given-names></name><name><surname>Middea</surname><given-names>E</given-names></name><name><surname>Giordano</surname><given-names>F</given-names></name><name><surname>Ando</surname><given-names>S</given-names></name></person-group><article-title>Estrogen receptor {alpha} binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor {gamma} signaling in breast cancer cells</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>6139</fpage><lpage>6147</lpage><pub-id pub-id-type="pmid">16144913</pub-id></citation></ref></ref-list></back></article> 